Percutaneous Ultrasound-Guided Laser Ablation with Contrast-Enhanced Ultrasonography for Hyperfunctioning Parathyroid Adenoma: A Preliminary Case Series

The study was to evaluate the safety and effectiveness of ultrasound-guided percutaneous laser ablation (pLA) as a nonsurgical treatment for primary parathyroid adenoma. Surgery was contraindicated in, or refused by, the included patients. No lesion enhancement on contrast-enhanced ultrasound immediately after pLA was considered “complete ablation.” Nodule size, serum calcium, and parathyroid hormone level were compared before and after pLA. Complete ablation was achieved in all 21 patients with 1 (n=20) or 2 (n=1) sessions. Nodule volume decreased from0.93±0.58 mL at baseline to0.53±0.38and0.48±0.34 mL at 6 and 12 months after pLA (P<0.05). At 1 day, 6 months, and 12 months after pLA, serum PTH decreased from15.23±3.00 pmol/L at baseline to7.41±2.79,6.95±1.78, and6.90±1.46 pmol/L, serum calcium decreased from3.77±0.77 mmol/L at baseline to2.50±0.72,2.41±0.37, and2.28±0.26 mmol/L, respectively (P<0.05). At 12 months, treatment success (normalization of PTH and serum calcium) was achieved in 81%. No serious complications were observed. Ultrasound-guided pLA with contrast-enhanced ultrasound is a viable alternative to surgery for primary parathyroid adenoma.

Download Full-text

Detection of the Single-Session Complete Ablation Rate by Contrast-Enhanced Ultrasound during Ultrasound-Guided Laser Ablation for Benign Thyroid Nodules: A Prospective Study

BioMed Research International ◽

10.1155/2016/9565364 ◽

2016 ◽

Vol 2016 ◽

pp. 1-8 ◽

Cited By ~ 8

Author(s):

Shuhua Ma ◽

Ping Zhou ◽

Xiaomin Wu ◽

Shuangming Tian ◽

Yongfeng Zhao

Keyword(s):

Laser Ablation ◽

Thyroid Nodules ◽

Ablation Rate ◽

Contrast Enhanced Ultrasound ◽

Single Session ◽

Ultrasound Guided ◽

Complete Ablation ◽

Contrast Enhanced ◽

Benign Thyroid Nodules ◽

Benign Thyroid

This study aimed to investigate the single-session complete ablation rate of ultrasound-guided percutaneous laser ablation (LA) for benign thyroid nodules. LA was performed in 90 patients with 118 benign thyroid nodules. Contrast-enhanced ultrasound (CEUS) was used to evaluate complete nodule ablation one day after ablation. Thyroid nodule volumes, thyroid functions, clinical symptoms and complications were evaluated 1, 3, 6, 12, and 18 months after ablation. Results showed that all benign thyroid nodules successfully underwent LA. The single-session complete ablation rates for nodules with maximum diameters ≤2 cm, 2-3 cm and ≥3 cm were 93.4%, 70.3% and 61.1%, respectively. All nodule volumes significantly decreased than that one day after ablation (P<0.05); at the final evaluation, the volume decreased from6.16±5.21 mL to0.05±0.01 mL. Thyroid functions did not show significant differences at one month after ablation compared with that before (P>0.05). Three patients had obvious pain during ablation; one (1.1%) had recurrent laryngeal nerve injury, but the voice returned to normal within 6 months after treatment. Thus, ultrasound-guided LA can effectively inactivate benign thyroid nodules. LA is a potentially viable minimally invasive treatment that offers good cosmetic effects.

Download Full-text